Abstract
Nanotechnology plays a significant role in the field of medicine and in drug delivery, mainly due to the major limitations affecting the conventional pharmaceutical agents, and older formulations and delivery systems. The effect of nanotechnology on healthcare is already being felt, as various nanotechnology applications have been developed, and several nanotechnology-based medicines are now on the market. Across many parts of the world, nanotechnology draws increasing investment from public authorities and the private sector. Most conventional drug-delivery systems (CDDSs) have an immediate, high drug release after administration, leading to increased administration frequency. Thus, many studies have been carried out worldwide focusing on the development of pharmaceutical nanomedicines for translation into products manufactured by local pharmaceutical companies. Pharmaceutical nanomedicine products are projected to play a major role in the global pharmaceutical market and healthcare system. Our objectives were to examine the nanomedicines approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in the global market, to briefly cover the challenges faced during their development, and to look at future perspectives. Additionally, the importance of nanotechnology in developing pharmaceutical products, the ideal properties of nanocarriers, the reasons behind the failure of some nanomedicines, and the important considerations in the development of nanomedicines will be discussed in brief.
Highlights
Nanotechnology and nanosciences are commonly seen as providing a significant advantage to many areas of study and applications [1]
Nanotechnology means the production and use of materials, equipment, and systems in nanoscale, which is an intermediate range between atoms and the molecular scale with the important prerequisite that at least one dimension is in the nanometer length [2,3]
Over the last 20 years, around 80 nanomedicine products have been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for marketing (Table 1)
Summary
Nanotechnology and nanosciences are commonly seen as providing a significant advantage to many areas of study and applications [1]. The effect of nanotechnology on healthcare is already being felt, as different nanotechnology ideas have been developed, and several nanotechnology-based medicines are available in the market. Since 1989, the number of approved nano-based pharmaceutical applications and products has significantly increased [1]. Over the last 20 years, around 80 nanomedicine products have been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for marketing (Table 1). This shows the importance of nanotechnology in the field of drug delivery. Our objectives were to sum up the different approved nanomedicines on the global market, to briefly cover the challenges faced during the development of nanomedicines, and to look at the future prospects
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
